2. Flowers H.L., Skoretz S.A., Silver F.L., et al. Poststroke Aphasia Frequency, Recovery, and Outcomes: A Systematic Review and Meta-Analysis. Arch. Phys Med. Rehabil. 2016;97(12):2188–201.e8. Doi: 10.1016/j.apmr.2016.03.006.

3. Bersano A., Burgio F., Gattinoni M., Candelise L. PROSIT Study Group Aphasia burden to hospitalised acute stroke patients: need for an early rehabilitation programme. Int J Stroke. 2009;4(6):443–47. Doi: 10.1111/j.1747- 4949.2009.00349.x.

4. Cichon N., Wlodarczyk L., Saluk-Bijak J., et al. Novel Advances to Post-Stroke Aphasia Pharmacology and Rehabilitation. J Clin Med. 2021;10(17):3778. Doi: 10.3390/ jcm10173778.

5. Dickey L., Kagan A., Lindsay M.P., et al. Black S. Incidence and profile of inpatient stroke-induced aphasia in Ontario, Canada. Arch Phys Med Rehabil. 2010;91(2):196–202. Doi: 10.1016/j. apmr.2009.09.020.

6. McNeil M.R., Pratt S.R. Defining aphasia: Some theoretical and clinical implications of operating from a formal definition. Aphasiology 2010;15(10):901–11. Doi: 10.1080/02687040143000276.

7. Kiran S., Thompson C.K. Neuroplasticity of Language Networks in Aphasia: Advances, Updates, and Future Challenges. Front Neurol. 2019;10:295. doi: 10.3389/fneur.2019.00295.

8. Кадыков А.С., Черникова Л.А., Шахпаронова Н.В. Реабилитация неврологических больных. М., 2009. 560 с.

9. Guyomard V., Fulcher R.A., Redmayne O., et al. Effect of dysphasia and dysphagia on inpatient mortality and hospital length of stay: a database study. J Am Geriatr Soc. 2009;57(11):2101–106. Doi: 10.1111/j.1532-5415.2009.02526.x.

10. Ellis C., Simpson A.N., Bonilha H., et al. The one-year attributable cost of poststroke aphasia. Stroke. 2012;43(5):1429–31. Doi: 10.1161/ STROKEAHA.111.647339.

11. Bullier B., Cassoudesalle H., Villain M., et al. New factors that affect quality of life in patients with aphasia. Ann Phys Rehabil Med. 2020;63(1):33– 7. Doi: 10.1016/j.rehab.2019.06.015.

12. Law J., Rush R., Pringle A.-M., et al. The incidence of cases of aphasia following first stroke referred to speech and language therapy services in Scotland. Aphasiology, 2009;23(10):1266–75. Doi: 10.1080/02687030802514953.

13. Hickok G. Poeppel D. The cortical organization of speech processing. Nat Rev Neurosci. 2007;8(5):393–402. Doi: 10.1038/nrn2113.

14. Corballis M.C. What’s left in language? Beyond the classical model. Ann N Y Acad Sci. 2015;1359:14–29. Doi: 10.1111/nyas.12761.

15. Hillis A.E., Barker P.B., Beauchamp N.J., et al. MR perfusion imaging reveals regions of hypoperfusion associated with aphasia and neglect. Neurology. 2000;55(6):782–88. Doi: 10.1212/wnl.55.6.782.

16. Кремнева Е.И., Коновалов Р.Н., Кротенкова М.В. и др. Картирование речевых структур головного мозга у здоровых людей с помощью функциональной магнитно-резонансной томографии. Лучевая диагностика и терапия.2012;3;65–72.

17. Crinion J., Price C.J. Right anterior superior temporal activation predicts auditory sentence comprehension following aphasic stroke. Brain. 2005;128(Pt. 12):2858–71. Doi: 10.1093/ brain/awh659.

18. Saur D., Lange R., Baumgaertner A., et al. Dynamics of language reorganization after stroke. Brain. 2006;129(Pt. 6):1371–84. Doi: 10.1093/ brain/awl090.

19. Crinion J.T., Leff A.P. Recovery and treatment of aphasia after stroke: functional imaging studies. Curr Opin Neurol. 2007;20(6):667–73. Doi: 10.1097/WCO.0b013e3282f1c6fa.

20. Winhuisen L., Thiel A., Schumacher B., et al. The right inferior frontal gyrus and poststroke aphasia: a follow-up investigation. Stroke. 2007;38(4):1286–92. Doi: 10.1161/01. STR.0000259632.04324.6c.

21. Белопасова А.В., Кадыков А.С., Коновалов Р.Н., Кремнева Е.Н. Организация нейрональной речевой сети у здоровых и ее реорганизация у пациентов с постинфарктной афазией. Анналы клинической и экспериментальной неврологии. 2012;6(4):52–6.

22. Инсульт: cовременные технологии диагностики и лечения: руководство для врачей. Под. ред. М.А. Пирадова, М.М. Танашян, М.Ю. Максимовой. М., 2018. 360 с.

23. Пирадов М.А., Максимова М.Ю., Танашян М.М. Инсульт: пошаговая инструкция. Руководство для врачей. М., 2020. 288 с.

24. Pulvermüller F., Neininger B., Elbert T., et al. Constraint-induced therapy of chronic aphasia after stroke. Stroke. 2001;32(7):1621–26. Doi: 10.1161/01.str.32.7.1621.

25. Zhang X., Shu B., Zhang D., et al. The Efficacy and Safety of Pharmacological Treatments for Post- stroke Aphasia. CNS Neurol. Disord. Drug Targets. 2018;17(7):509–21. Doi: 10.2174/1871527317666180706143051.

26. Berthier M.L., Pulvermüller F., Dávila G., et al. Drug therapy of post-stroke aphasia: a review of current evidence. Neuropsychol Rev. 2011;21(3):302– 17. Doi: 10.1007/s11065-011-9177-7.

27. Winstein C.J., Stein J., Arena R., et al. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research. Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016;47(6):e98–169. Doi: 10.1161/ STR.0000000000000098.

28. Seyedsaadat S.M., Kallmes D. Memantine for the treatment of ischemic stroke: experimental benefits and clinical lack of studies. Rev Neurosci. 2019;30(2):203–20. Doi: 10.1515/ revneuro-2018-0025.

29. Chen B., Wang G., Li W., et al. Memantine attenuates cell apoptosis by suppressing the calpain-caspase-3 pathway in an experimental model of ischemic stroke. Among authors: chen l. Exp Cell Res. 2017;351(2):163–72. Doi: 10.1016/j.yexcr.2016.12.028.

30. Martin H.G., Wang Y.T. Blocking the deadly effects of the NMDA receptor in stroke. Cell. 2010;140(2):174–76. Doi: 10.1016/j. cell.2010.01.014.

31. MartInez-Coria H., Arrieta-Cruz I., Cruz M.E., L pez-Vald s H.E. Physiopathology of ischemic stroke and its modulation using memantine: evidence from preclinical stroke. Neural Regen Res. 2021;16(3):433–39. Doi: 10.4103/1673- 5374.293129.

32. Wang Y., Du W., Yang X., et al. Diagnosis and differential diagnosis flow diagram of Chinese post-stroke aphasia types and treatment of post-stroke aphasia. Aging Med. (Milton) Actions. 2021;4(4):325–36. Doi: 10.1002/ agm2.12183.

33. Lipton S.A. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007;8(5):621–32. Doi: 10.2174/138945007780618472.

34. Berthier M.L., Green C., Lara J.P., et al. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol. 2009;65(5):577–85. Doi: 10.1002/ana.21597.

35. Rogawski M.A., Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS. Drug Rev. 2003;9(3):275–308. Doi: 10.1111/j.1527-3458.2003.tb00254.x.

36. First drug for moderate-to-severe Alzheimer’s. FDA Consum. 2004;38(1):3.

37. Marvanová M., Lakso M., Pirhonen J., et al. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci. 2001;18(3):247–58. Doi: 10.1006/ mcne.2001.1027.

38. Meisner F., Scheller C., Kneitz S., et al. German Competence Network HIV/AIDS. Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacol. 2008;33(9):2228–36. Doi: 10.1038/ sj.npp.1301615.

39. Réus G.Z., Stringari R.B., Kirsch T.R., et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res Bull. 2010;81(6):585–89. Doi: 10.1016/j.brainresbull.2009.11.013.

40. Wu H.M., Tzeng N.S., Qian L., et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacol. 2009;34(10):2344–57. Doi: 10.1038/ npp.2009.64.

41. Jantas D., Szymanska M., Budziszewska B., Lason W. An involvement of BDNF and PI3-K/ Akt in the anti-apoptotic effect of memantine on staurosporine-evoked cell death in primary cortical neurons. Apoptosis. 2009;14(7):900–12. Doi: 10.1007/s10495-009-0370-6.

42. Rosi S., Ramirez-Amaya V., Vazdarjanova A., et al. Accuracy of hippocampal network activity is disrupted by neuroinflammation: rescue by memantine. Brain. 2009;132(Pt. 9):2464–77. Doi: 10.1093/brain/awp148.

43. Wang Y.C., Sanchez-Mendoza E.H., Doeppner T.R., Hermann D.M. Post-acute delivery of memantine promotes post-ischemic neurological recovery, peri-infarct tissue remodeling, and contralesional brain plasticity. J Cereb Blood Flow Metab. 2017;37(3):980–93. Doi: 10.1177/0271678X16648971.

44. Levine D.A., Langa K.M. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurothers. 2011;8(3):361–73. Doi: 10.1007/s13311-011-0047-z.

45. Orgogozo J.M., Rigaud A.S., Stöffler A., et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834–39. Doi: 10.1161/01.str.0000020094.08790.49.

46. Wilcock G., M bius H.J., St ffler A. MMM 500 group.A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17(6):297–305. Doi: 10.1097/00004850-200211000-00005.

47. Tocco M., Bayles K., Lopez O., et al. (2014). Effects of memantine treatment on language abilities and functional communication: A review of data. Aphasiol. 2013;28(2):236–57. Doi: 10.1080/02687038.2013.838617.

48. Barbancho M.A., Berthier M.L., Navas-S nchez P., et al. Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An. ERP. study. Brain Lang. 2015;145–6:1–10. Doi: 10.1016/j.bandl.2015.04.003.